MicroRNA miR-466 inhibits Lymphangiogenesis by targeting prospero-related homeobox 1 in the alkali burn corneal injury model

Journal of Biomedical Science

Volumn 22, Issue 1, 2015, Pages

  Seo, Minkoo ^a   Choi, Jun Sub ^a   Rho, Chang Rae ^a,b   Joo, Choun Ki ^a,c   Lee, Suk Kyeong ^a  

^a The Catholic University of Korea   (South Korea)

^b Daejeon St Mary's Hospital   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

Alkali burn; Cornea transplantation; Lymphangiogenesis; MicroRNA; miR 181; miR 466; Prox1; Tube formation

Indexed keywords

LUCIFERASE; MESSENGER RNA; MICRORNA; MICRORNA 4305; MICRORNA 466; MICRORNA 4795 5P; PROSPERO HOMEOBOX 1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ALKALI; HOMEODOMAIN PROTEIN; MIRN466 MICRORNA, HUMAN; PROSPERO-RELATED HOMEOBOX 1 PROTEIN; TUMOR SUPPRESSOR PROTEIN;

3' UNTRANSLATED REGION; ANGIOGENESIS; ANIMAL MODEL; ARTICLE; BIOINFORMATICS; CAUSTIC BURN; CONTROLLED STUDY; CORNEA BURN; CORNEA TRANSPLANTATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GRAFT REJECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RAT; ANIMAL; BURNS, CHEMICAL; CHEMICALLY INDUCED; CORNEA INJURY; DISEASE MODEL; EYE BURN; GENETICS; METABOLISM; SPRAGUE DAWLEY RAT;

PROSPERO; RATTUS;

ALKALIES; ANIMALS; BURNS, CHEMICAL; CORNEAL INJURIES; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; EYE BURNS; HOMEODOMAIN PROTEINS; HUMANS; LYMPHANGIOGENESIS; MALE; MICRORNAS; RATS; RATS, SPRAGUE-DAWLEY; TUMOR SUPPRESSOR PROTEINS;

EID: 84927740958     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/s12929-014-0104-0     Document Type: Article

References (44)

1. Panda A, Vanathi M, Kumar A, Dash Y, Priya S: Corneal graft rejection. Surv Ophthalmol 2007, 52:375-396.
2. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP: Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999, 285:245-248.
3. Zhang P, Wu D, Ge J, Zhu Z, Feng G, Yue T, Lin J, Zheng H: Experimental inhibition of corneal neovascularization by endostatin gene transfection in vivo. Chin Med J (Engl) 2003, 116:1869-1874.
4. Ling S, Lin H, Xiang D, Feng G, Zhang X: Clinical and experimental research of corneal lymphangiogenesis after keratoplasty. Ophthalmologica 2008, 222:308-316.
5. Cursiefen C, Chen L, Dana MR, Streilein JW: Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology. Cornea 2003, 22:273-281.
6. Liu Y, Hamrah P, Zhang Q, Taylor AW, Dana MR: Draining lymph nodes of corneal transplant hosts exhibit evidence for donor major histocompatibility complex (MHC) class II-positive dendritic cells derived from MHC class II-negative grafts. J Exp Med 2002, 195:259-268.
7. Otrock ZK, Mahfouz RA, Makarem JA, Shamseddine AI: Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells Mol Dis 2007, 39:212-220.
8. Matsumoto T, Claesson-Welsh L: VEGF receptor signal transduction. Sci STKE 2001, 2001:re21.
9. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K: A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. Embo j 1996, 15:1751.
10. Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA: Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A 1998, 95:548-553.
11. Tammela T, Alitalo K: Lymphangiogenesis: Molecular mechanisms and future promise. Cell 2010, 140:460-476.
12. Oliver G, Sosa-Pineda B, Geisendorf S, Spana EP, Doe CQ, Gruss P: Prox 1, a prospero-related homeobox gene expressed during mouse development. Mech Dev 1993, 44:3-16.
13. Wigle JT, Harvey N, Detmar M, Lagutina I, Grosveld G, Gunn MD, Jackson DG, Oliver G: An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. Embo j 2002, 21:1505-1513.
14. Hong YK, Harvey N, Noh YH, Schacht V, Hirakawa S, Detmar M, Oliver G: Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate. Dev Dyn 2002, 225:351-357.
15. Hong YK, Detmar M: Prox1, master regulator of the lymphatic vasculature phenotype. Cell Tissue Res 2003, 314:85-92.
16. Dietrich T, Bock F, Yuen D, Hos D, Bachmann BO, Zahn G, Wiegand S, Chen L, Cursiefen C: Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J Immunol 2010, 184:535-539.
17. Flister MJ, Wilber A, Hall KL, Iwata C, Miyazono K, Nisato RE, Pepper MS, Zawieja DC, Ran S: Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-kappaB and Prox1. Blood 2010, 115:418-429.
18. Petrova TV, Makinen T, Makela TP, Saarela J, Virtanen I, Ferrell RE, Finegold DN, Kerjaschki D, Yla-Herttuala S, Alitalo K: Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. Embo j 2002, 21:4593-4599.
19. Harvey NL, Srinivasan RS, Dillard ME, Johnson NC, Witte MH, Boyd K, Sleeman MW, Oliver G: Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause adult-onset obesity. Nat Genet 2005, 37:1072-1081.
20. Perron MP, Provost P: Protein interactions and complexes in human microRNA biogenesis and function. Front Biosci 2008, 13:2537-2547.
21. Kazenwadel J, Michael MZ, Harvey NL: Prox1 expression is negatively regulated by miR-181 in endothelial cells. Blood 2010, 116:2395-2401.
22. Pedrioli DM, Karpanen T, Dabouras V, Jurisic G, van de Hoek G, Shin JW, Marino D, Kalin RE, Leidel S, Cinelli P, Schulte-Merker S, Brandli AW, Detmar M: miR-31 functions as a negative regulator of lymphatic vascular lineage-specific differentiation in vitro and vascular development in vivo. Mol Cell Biol 2010, 30:3620-3634.
23. Arnaoutova I, George J, Kleinman HK, Benton G: The endothelial cell tube formation assay on basement membrane turns 20: state of the science and the art. Angiogenesis 2009, 12:267-274.
24. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP: MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 2007, 27: 91-105.
25. Sasahira T, Ueda N, Yamamoto K, Kurihara M, Matsushima S, Bhawal UK, Kirita T, Kuniyasu H: Prox1 and FOXC2 act as regulators of lymphangiogenesis and angiogenesis in oral squamous cell carcinoma. PLoS One 2014, 9:e92534.
26. Harada K, Yamazaki T, Iwata C, Yoshimatsu Y, Sase H, Mishima K, Morishita Y, Hirashima M, Oike Y, Suda T, Miura N, Watabe T, Miyazono K: Identification of targets of Prox1 during in vitro vascular differentiation from embryonic stem cells: functional roles of HoxD8 in lymphangiogenesis. J Cell Sci 2009, 122:3923-3930.
27. Augustin HG, Koh GY, Thurston G, Alitalo K: Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009, 10:165-177.
28. Cao Y, Linden P, Farnebo J, Cao R, Eriksson A, Kumar V, Qi JH, Claesson-Welsh L, Alitalo K: Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci U S A 1998, 95:14389-14394.
29. Druz A, Chu C, Majors B, Santuary R, Betenbaugh M, Shiloach J: A novel microRNA mmu-miR-466 h affects apoptosis regulation in mammalian cells. Biotechnol Bioeng 2011, 108:1651-1661.
30. Dimmeler S, Zeiher AM: Endothelial cell apoptosis in angiogenesis and vessel regression. Circ Res 2000, 87:434-439.
31. Folkman J: Angiogenesis and apoptosis. Semin Cancer Biol 2003, 13:159-167.
32. Druz A, Betenbaugh M, Shiloach J: Glucose depletion activates mmu-miR-466 h-5p expression through oxidative stress and inhibition of histone deacetylation. Nucleic Acids Res 2012, 40: 7291-7302.
33. Li Y, Fan X, He X, Sun H, Zou Z, Yuan H, Xu H, Wang C, Shi X: MicroRNA-466 l inhibits antiviral innate immune response by targeting interferon-alpha. Cell Mol Immunol 2012, 9:497-502.
34. Luo Y, Liu Y, Liu M, Wei J, Zhang Y, Hou J, Huang W, Wang T, Li X, He Y, Ding F, Yuan L, Cai J, Zheng F, Yang JY: Sfmbt2 10th intron-hosted miR-466(a/e)-3p are important epigenetic regulators of Nfat5 signaling, osmoregulation and urine concentration in mice. Biochim Biophys Acta 1839, 2014:97-106.
35. Yan X, Chen X, Liang H, Deng T, Chen W, Zhang S, Liu M, Gao X, Liu Y, Zhao C, Wang X, Wang N, Li J, Liu R, Zen K, Zhang CY, Liu B, Ba Y: miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer. Mol Cancer 2014, 13:220.
36. Renjie W, Haiqian L: MiR-132, miR-15a and miR-16 synergistically inhibit pituitary tumor cell proliferation, invasion and migration by targeting Sox5. Cancer Lett 2015, 356:568-578.
37. Ferrara N, Hillan KJ, Gerber HP, Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004, 3:391-400.
38. Syrigos KN, Karapanagiotou E, Boura P, Manegold C, Harrington K: Bevacizumab-induced hypertension: pathogenesis and management. BioDrugs 2011, 25:159-169.
39. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25:1539-1544.
40. Spaide RF, Fisher YL: Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006, 26:275-278.
41. Waisbourd M, Shemesh G, Kurtz S, Rachmiel R, Moisseiev E, Zayit-Soudri S, Loewenstein A, Barequet I: Topical bevacizumab for neovascular glaucoma: a pilot study. Pharmacology 2014, 93:108-112.
42. Awadein A: Subconjunctival bevacizumab for vascularized rejected corneal grafts. J Cataract Refract Surg 2007, 33:1991-1993.
43. Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, Zahn G, Cursiefen C: Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007, 48:2545-2552.
44. Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF, Detmar M: VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 2005, 201:1089-1099.